Back to Journals » Drug Design, Development and Therapy » Volume 17

Orcinol Glucoside Facilitates the Shift of MSC Fate to Osteoblast and Prevents Adipogenesis via Wnt/β-Catenin Signaling Pathway [Retraction]

Authors Zhou X, Liu Z , Huang B , Yan H , Yang C , Li Q, Jin D 

Received 24 March 2023

Accepted for publication 24 March 2023

Published 28 March 2023 Volume 2023:17 Pages 959—960

DOI https://doi.org/10.2147/DDDT.S414031



Zhou X, Liu Z, Huang B, et al. Drug Des Devel Ther. 2019;13:2703–2713.

The Editor and Publisher of Drug Design, Development and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of Oil Red O images in Figures 4 and Figure 6. Specifically,

  • Figure 4C, Oil Red O, Ctrl, appears to have been duplicated with the same image for Figure 6D, Oil Red O, OG+ICG-001.

The authors cooperated with the investigation and provided data associated with the study. However, despite the authors’ assistance, it was still not clear how the images came to be duplicated, and, as we cannot verify the validity of the published work, we are therefore retracting the article and the authors agree with this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.